<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547300</url>
  </required_header>
  <id_info>
    <org_study_id>NEB-MD-03</org_study_id>
    <nct_id>NCT00547300</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension</brief_title>
  <official_title>Tolerability of Nebivolol Compared With Metoprolol ER in Patients With Mild to Moderate Hypertension Taking Hydrochlorothiazide (HCTZ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Forest Laboratories</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the tolerability of nebivolol to metoprolol ER in a
      general population of patients with mild to moderate hypertension receiving
      hydrochlorothiazide (HCTZ)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an 18-week study to evaluate the tolerability of nebivolol compared to
      metoprolol ER in outpatients with mild to moderate hypertension taking HCTZ. It is a
      multi-center, randomized, double blind (DB), active-control, parallel-group study, starting
      with a 4-week HCTZ run-in phase, followed by a 12-week DB treatment phase. Patients meeting
      the entry criteria at the end of run-in are randomized to one of two treatment groups,
      nebivolol or metoprolol ER. Up-titration of dose of study drug will occur if needed during
      the first 4 weeks of the DB phase, after which there is an 8-week stable-dose period of
      treatment. A 2-week double-blind withdrawal phase follows, during which tapering off study
      drug occurs.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 31, 2007</start_date>
  <completion_date type="Actual">January 2, 2008</completion_date>
  <primary_completion_date type="Actual">January 2, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Patient Symptoms Questionnaire (PSQ) Derived Score</measure>
    <time_frame>Measurements occured over a 14 week period, from Visit 2 (Week -2) to Visit 10 (Week 12)</time_frame>
    <description>The PSQ contained 44 possible symptoms rated from 0 (no discomfort) to 5 (extreme discomfort).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Pressure (BP)</measure>
    <time_frame>Measurements occured over a 18 week period, from Visit 1 (Week -4) through Visit 11 (Week 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>Measurements occured over a 18 week period, from Visit 1 (Week -4) through Visit 11 (Week 14)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol ER</intervention_name>
    <description>Metoprolol ER once daily, oral administration</description>
    <arm_group_label>Metoprolol ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol once daily, oral administration</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, ambulatory outpatients

          -  History of hypertension being treated with two medications, one of which must be HCTZ
             and the other of which must not be a beta-blocker or clonidine

          -  SBP of 135-155 mm Hg and/or DBP of &gt;85 mm Hg at screening (Visit 1)

          -  SBP of 140-165 mm Hg and DBP &gt; 90 mmHg at randomization (Visit 3)

        Exclusion Criteria:

          -  Treatment with a beta-blocker or clonidine within 6 months of screening (Visit 1)

          -  Clinically significant respiratory disease (e.g., bronchial asthma, reactive airways
             disease, chronic obstructive pulmonary disease)

          -  Coronary artery disease requiring treatment with a calcium channel blocker or nitrates

          -  Clinically significant cardiovascular disease (e.g., myocardial infarction,
             cerebrovascular event, significant arrhythmia) within 6 months of screening (Visit 1)

          -  History of severe mental illness (including Major Depressive Disorder, psychosis,
             dementia, bipolar disorder) within 6 months of screening (Visit 1)

          -  Use of antipsychotic medication (e.g., dopamine receptor antagonists, serotonin
             dopamine receptor antagonists) or antidepressants

          -  Diabetes mellitus, type I or II

          -  Participation in a previous investigational study of nebivolol at any time

          -  Receipt of treatment with an investigational study drug within 30 days of screening
             (Visit 1)

          -  History of hypersensitivity to nebivolol, metoprolol ER, other beta-blockers, HCTZ, or
             other sulfonamide-derived drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Forest Research Institute 014</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 028</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 054</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 025</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 013</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 053</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 052</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 033</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 010</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 019</name>
      <address>
        <city>Holly Hill</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 036</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 007</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 009</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 006</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 027</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 050</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 039</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 002</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 032</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 008</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 003</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 012</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 048</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute 040</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://frx.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://mylan.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <results_first_submitted>October 19, 2010</results_first_submitted>
  <results_first_submitted_qc>April 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2019</results_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Nebivolol</keyword>
  <keyword>Beta blocker</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment occurred over a four month period from October 2007 to January 2008 at 39 US sites.</recruitment_details>
      <pre_assignment_details>All patients went through a 4 week hydrochlorothiazide (HCTZ) run-in phase before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol Extended-Release (ER)</title>
          <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26">Two (2) patients were randomized in error, but no study medication taken.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No patients completed because the study was administratively terminated.</participants>
                <participants group_id="P2" count="0">No patients completed because the study was administratively terminated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was Administratively Terminated</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Meet Entry Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol Extended-Release (ER)</title>
          <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="8.67"/>
                    <measurement group_id="B2" value="57.0" spread="9.32"/>
                    <measurement group_id="B3" value="56.0" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Patient Symptoms Questionnaire (PSQ) Derived Score</title>
        <description>The PSQ contained 44 possible symptoms rated from 0 (no discomfort) to 5 (extreme discomfort).</description>
        <time_frame>Measurements occured over a 14 week period, from Visit 2 (Week -2) to Visit 10 (Week 12)</time_frame>
        <population>Formal analysis of the primary endpoint was not conducted in this abbreviated study as the study was terminated before visit 10 was reached.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Extended-Release (ER)</title>
            <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Patient Symptoms Questionnaire (PSQ) Derived Score</title>
          <description>The PSQ contained 44 possible symptoms rated from 0 (no discomfort) to 5 (extreme discomfort).</description>
          <population>Formal analysis of the primary endpoint was not conducted in this abbreviated study as the study was terminated before visit 10 was reached.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Blood Pressure (BP)</title>
        <time_frame>Measurements occured over a 18 week period, from Visit 1 (Week -4) through Visit 11 (Week 14)</time_frame>
        <population>Formal analysis of the secondary endpoint was not conducted in this abbreviated study as the study was terminated before all visits were completed. No patients completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Extended-Release (ER)</title>
            <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood Pressure (BP)</title>
          <population>Formal analysis of the secondary endpoint was not conducted in this abbreviated study as the study was terminated before all visits were completed. No patients completed the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate</title>
        <time_frame>Measurements occured over a 18 week period, from Visit 1 (Week -4) through Visit 11 (Week 14)</time_frame>
        <population>Formal analysis of the secondary endpoint was not conducted in this abbreviated study as the study was terminated before all visits were completed. No patients completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Extended-Release (ER)</title>
            <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate</title>
          <population>Formal analysis of the secondary endpoint was not conducted in this abbreviated study as the study was terminated before all visits were completed. No patients completed the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data was collected over a four month period from October 2007 to January 2008.</time_frame>
      <desc>Non-serious adverse events based on the safety population of (n=49).</desc>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>Nebivolol 5 mg, 10 mg or 20 mg</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol Extended-Release (ER)</title>
          <description>Metoprolol ER 50 mg, 100 mg or 200 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor can review results communications prior to public release &amp; can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info &amp; shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to administrative reasons. Formal analyses of primary and secondary endpoints were not conducted in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

